Devin Wiley

Devin Wiley is a co-founder and chief medical officer of Circumvent Pharmaceuticals, a company focused on advancing a first therapeutic option for CLN1 Batten Disease, an ultra-rare form of rapid neurodegeneration in infants. In addition to his work with Circumvent, Devin serves on the Clinical Advisory Board at Intel, and he manages the development of a new technology platform that integrates microelectronics and pharmaceuticals, as a co-founder and CEO of Velanidi Technologies LLC. Devin received his M.D. at the University of Southern California and his Ph.D. in Chemical Engineering from Caltech.